FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BENNETT C FRANK						2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [ IONS ]									k all app Direc	tionship of Reportii all applicable) Director Officer (give title		10% Ov	
(Last) 2855 GA	(Last) (First) (Middle) 2855 GAZELLE COURT						3. Date of Earliest Transaction (Month/Day/Year) 09/28/2023								below	below)  EVP, Chief Sc		below)	·
(Street) CARLSBAD CA 92010					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X					
(City)	(State) (Zip)				Rule 10b5-1(c) Transaction Indication														
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	enefi	cially	Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)					Executive (Executive)		Deemed ecution Date, ny onth/Day/Year)				es Acquired (A Of (D) (Instr. 3,		4 and Secu Bene Own		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or Pri	се	Report Transa (Instr. 3	action(s) 3 and 4)			(Instr. 4)
Common Stock 09/28/2						2023					<b>4,460</b> <sup>(1)</sup>	D	\$	46.5	65,754			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	n Date, Transaction Code (Inst				6. Date Exercisab Expiration Date (Month/Day/Year)		ite	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Dei Sec (Ins	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
							(A)	(D)	Date Exercisable		Expiration Date	Title	or Number of Shares						

## **Explanation of Responses:**

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 29, 2023

By: Patrick R. O'Neil, 09/29/2023 attorney-in-fact For: C. Frank **Bennett** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.